Allogeneic BMT is potentially curative for patients with acute myelogenous leukemia (AML) in first remission. However, many patients relapse after transplantation. Various immunotherapeutic options have been attempted with variable success in preventing relapse. Early identification of patients at high risk for relapse could allow prompt intervention. We examined the effect of slow lymphocyte recovery after siblingmatched allogeneic BMT on the risk of relapse in patients with AML. We also examined the effect of prednisone-containing GVHD prophylaxis on the rate of lymphocyte recovery. Patients with absolute lymphocyte count (ALC) Ͻ150 × 10 6 /l by day +30 had a 3.5-fold higher risk of relapse (P = 0.0088) and a lower overall survival (P = 0.0079) than patients with a higher ALC. We did not find correlation between lymphocyte count determined earlier in the post-transplantation course (day +21) and the risk of relapse. Patients receiving prednisone had a significantly lower ALC at day +30 than those who did not receive prednisone (289 vs 549 × 10 6 /l, P = 0.002). We conclude that a slow lymphocyte recovery after allogeneic BMT for AML is strongly predictive of subsequent relapse and that the type of GVHD prophylaxis should be considered when analyzing lymphocyte recovery. Bone Marrow Transplantation (2001) 28, 951-956. Keywords: allogeneic; bone marrow transplantation; cyclosporine; lymphocyte recovery; prophylaxis; relapse Allogeneic BMT offers the potential for cure in patients with acute myelogenous leukemia (AML). Several studies of allogeneic BMT have shown a benefit for patients in first remission with high-risk AML.
ing FAB type, 6 associated karyotypic abnormalities, 7 stage of the disease, conditioning regimen used, 3 ,5 GVHD prophylaxis, 6 and development of acute and chronic GVHD, have been shown to influence the incidence of relapse after allogeneic BMT for AML. Therapeutic options are limited for those who relapse, as they tolerate further chemotherapy poorly, and repeat transplants have limited efficacy. 8, 9 Immunotherapy offers a new approach to patients who relapse after allogeneic BMT. This has mostly been in the form of donor lymphocyte infusions (DLI), and several reports have demonstrated long-term survival with this approach. [10] [11] [12] [13] These results have led to evaluation of its role in preventing relapse; however, DLI is also associated with a risk of severe GVHD. Other approaches for prevention of relapse have included the use of cytokines like interferon-alpha (IFN-␣) and interleukin-2 (IL-2) or rapid withdrawal of immunosuppression. Since only a quarter to a third of patients relapse after allogeneic BMT, a need exists for prognostic variables that can prospectively identify patients at risk for relapse and thereby help select appropriate patients for prophylactic immunotherapy.
Slow recovery of the lymphocyte count after allogeneic BMT has been proposed as a predictor of increased risk of relapse after allogeneic BMT for AML. 14 We retrospectively examined the lymphocyte counts 3 weeks (day +21) and 1 month (day +30) after matched related donor allogeneic transplants for AML to determine the effect of lymphocyte recovery on the risk of subsequent relapse. The day +21 lymphocyte count was assessed to determine whether we could identify patients at risk earlier than previously reported. The commonly used regimens for prophylaxis against GVHD have included cyclosporine combined with either methotrexate or prednisone or both. However, prednisone use is often accompanied by lymphocytopenia; hence, the prophylactic regimen could potentially have a direct effect on post-transplant lymphocyte recovery. Therefore, we also examined the effect of the GVHD prophylaxis regimen on lymphocyte recovery in our group of patients.
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Methods
We reviewed retrospectively the database of patients who had undergone allogeneic BMT at our institution between 1982 and 1999 and identified 87 patients who had undergone allogeneic BMT for AML. Syngeneic transplantations and PBSC transplantations were excluded. The medical records were reviewed, and data for day +21 and day +30 leukocyte counts, both total and differential, were collected. The group was heterogeneous for type of GVHD prophylaxis and disease status at transplantation. Patients in their first remission were considered to have nonadvanced disease; all others, advanced. Patient characteristics are shown in Table 1 . Seventy-eight patients who survived at least 21 days post transplant were considered for analysis of the effect of the day +21 lymphocyte count on relapse; of these 78 patients, 75 who survived at least 30 days were considered for analysis of the effect of day +30 absolute lymphocyte count (ALC).
Conditioning regimens
The conditioning regimen used most frequently was cyclophosphamide (120 mg/kg) with fractionated TBI (1320 cGy). The other preparative regimens included busulfan (16 mg/kg) and cyclophosphamide (120 mg/kg) or etoposide (60 mg/kg) with TBI.
GVHD prophylaxis
Combinations of cyclosporine and methotrexate or cyclosporine and prednisone were the prophylaxis regimens used (Table 1) . Acute GVHD was treated with methylprednisolone at a dose of 1 to 2 mg/kg as soon as the diagnosis was confirmed.
Endpoints
Relapse after transplantation was the primary endpoint. Remission and relapse were defined by conventional criteria. Treatment-related mortality was defined as death related directly to toxicity from the conditioning regimen or to other causes related to transplantation in patients free of disease or to both.
Statistical analysis
The 2 test was used to compare nominal variables between the two groups; the t-test, to compare numerical variables. The Kaplan-Meier product limit method was used for analysis of relapse-free survival and overall survival. Logrank tests were used to compare survival curves. Patients were censored at the time of death (without relapse) or at the last follow-up for estimating relapse-free survival. The Cox proportional hazards model was used to compare the risk of relapse between the two groups. The study protocol was reviewed and approved by the Mayo Foundation Institutional Review Board.
Results
The median follow-up for the group was 26 months (range, 1-213 months), with 64 patients surviving at least 100 days post transplant; 55 patients were free of relapse. Twentysix patients relapsed after a median duration of 178 days (range, 28 days to 6.7 years); 22 of these patients are dead (17 from progressive disease) and four are alive after salvage therapy, including second transplants and DLI. Twenty-five patients died of transplantation-related complications and late infections without evidence of recurrent disease. Thirty-six patients have been free of disease and were alive in continuous remission at a median follow-up of 72.5 months (range, 3-213 months).
Seventy-eight patients survived at least 21 days post transplant. Seventy-three patients for whom the day +21 lymphocyte counts were available were classified into two groups according to their ALC, and the effect of the ALC on the risk of relapse was analyzed. The risk was examined at several levels of ALC, including 100 × 10 /l, with a Cox proportional hazards analysis. At none of these levels did the ALC reliably predict the risk for relapse. We also examined the effect of the day +21 lymphocyte count on overall survival. Overall survival did not differ between the two groups at any level of the day +21 lymphocyte count. Similarly, the effect of lymphocyte count at day +30 was examined at 125 × 10 /l, and 225 × 10 6 /l for the 75 relapse-free patients for whom the ALC on day 30 was available ( Table 2) . A trend toward a higher risk of relapse was present with lower ALC at all levels, but these differences were statistically significant only at levels of ALC of 150 × 10 6 /l and 175 × 10 6 /l. The most significant differences were seen at a level of ALC of 150 × 10 6 /l. Patients who had an ALC less than 150 × 10 6 /l at day +30 were at a significantly higher risk of relapse than those with greater lymphocyte counts (relative risk, 3.51; 95% confidence interval, 1.37-8.90; P = 0.0088). The relapse-free survival was also significantly different between the two groups (P = 0.0079) (Figure 1) . Patients who had a slow recovery of their lymphocyte count also had a significantly lower overall survival compared with the other patients (P = 0.0047) (Figure 2) .
We analyzed the effect of the GVHD prophylaxis regimen on the day +30 lymphocyte count. The patients in this group received various forms of GVHD prophylaxis ( Table 1 ). The patients were assigned to two groups depending on whether or not they received prednisone as part of their GVHD prophylaxis. Among the 75 patients, 26 patients received a regimen with prednisone and the other 49 received prophylaxis without prednisone, which was mostly cyclosporine and methotrexate. Patients who received prednisone as part of their GVHD prophylaxis had a significantly lower lymphocyte count (289 ± 44 × 10 at day +30 than the other group (549 ± 55 × 10 6 /l) (P = 0.0022). Even after stratifying for the type of GVHD prophylaxis, the day +30 ALC was a significant predictive factor for the risk of relapse; those patients who had day +30 ALC Ͻ150 × 10 6 /l had a higher risk of relapse (relative risk, 3.31; 95% confidence interval, 1.19-9.20; P = 0.022).
We also analyzed the effect of other variables on the risk of relapse. In a multivariate analysis including age at transplantation, disease status (advanced or nonadvanced), HLA match, gender, conditioning regimen, and development of acute GVHD, the ALC was significant for those patients with a day +30 ALC less than 150 × 10 6 /l, showing an 8.24-fold greater risk of relapse (P = 0.0014) ( Table 3) . No correlation existed between development of acute GVHD and lymphocyte recovery.
Discussion
Our data confirm previous observations about the prognostic value of the rate of lymphocyte recovery after allogeneic BMT.
14 It has become clear over the years that allogeneic BMT for hematologic malignancies is effective through two major mechanisms: (1) tumor reduction by the conditioning regimen and (2) elimination of minimal residual disease through the graft-versus-tumor effect. The relative contribution of each component is still debated, and it probably depends on the diagnosis and phase of a patient's disease, as has been recently demonstrated by non-myeloablative transplantations. 15, 16 
Bone Marrow Transplantation
Substantial evidence indicates that donor-derived lymphocytes are important in the eradication of leukemia after allogeneic BMT. [17] [18] [19] [20] Cluster of differentiation (CD) 4 and CD8 cells, as well as natural killer (NK) cells, 21, 22 have been implicated in the genesis of the GVL effect. 23, 24 Increased numbers of activated T cells (DR + ) have been noted in the early post-transplantation period. 25, 26 NK cells seem to be capable of mounting a GVL reaction independent of any development of GVHD. [27] [28] [29] It is likely that these immunological mechanisms would be most effective during the early post-transplantation period, given the smaller bulk of disease at that time. However, lymphocyte recovery after BMT is often substantially delayed. After related marrow transplants, the total lymphocyte count returns to normal by about 3 months post transplantation. 30, 31 However, the total number of T cells, especially CD4 + T cells, remains low for up to 12 months post transplantation (even longer in patients who develop chronic GVHD) in contrast to the number of CD8 + cells, which usually quickly returns to normal. 22, 32 During the early post-transplantation period, when the majority of the peripheral blood mononuclear cells are NK cells, the concentration of NK cells increases rapidly. 33 ,34 NK cells are capable of mediating cytotoxicity without prior sensitization and may be responsible for most of the early antileukemic activity of the graft. 35 Slow recovery of NK cells and CD8 + cells after allogeneic BMT has been correlated with an increased risk of relapse. 22 Conceivably, patients in our study who had a slow recovery of lymphocyte counts had decreased numbers of NK cells and T cells during the early post-transplantation period, thus depriving them of the GVL effect and leading to an increased risk of relapse. The independence of this observation from the incidence of acute GVHD again emphasizes the potential importance of NK cells in the initiation of the GVL effect. Unfortunately, the retrospective nature of our study precludes a detailed analysis of lymphocyte subsets, which would have been more informative in understanding some of the mechanisms behind this observation.
Early identification of patients with AML who are at a high risk of relapse could potentially allow intervention specifically aimed at its prevention. This could take the form of a rapid taper of immunosuppression, 36 use of DLI, or initiation of interferon or interleukins (eg IL-2 or IL-12). Prophylactic use of DLI after allogeneic BMT for acute leukemia has decreased relapse rates but is associated with an increased incidence of GVHD.
37,38 IL-2 has been shown to enhance the cytotoxicity of NK cells against various cell lines 39, 40 and to decrease the relapse rate after T celldepleted allogeneic BMT. 41 Interferon-␣ has had a favorable effect on the relapse rates after allogeneic BMT. 42, 43 In our study, we observed a decrease in the overall survival among patients who had a slow recovery of lymphocyte counts. Similar observations were made by Pavletic et al 44 among patients after allogeneic blood stem cell transplantation (SCT). In our study, infections and transplantrelated toxicity accounted for most of the excess deaths in the slow recovery group. Faster lymphocyte recovery may be a sign of more rapid immune reconstitution leading to fewer infections and deaths. 45 Decreased post-transplantation lymphocyte counts have been associated with CMV infection 46 as well as with increased mortality from CMV disease. 47 Increased risk of relapse among our patients with slower lymphocyte recovery also contributed to a decrease in overall survival in this group.
However, a striking observation in our group of patients was the effect of GVHD prophylaxis on the rate of lymphocyte recovery. Patients receiving prednisone as part of GVHD prophylaxis had a slower recovery of lymphocyte counts. Although glucocorticoids can be cytolytic to thymocytes and immature lymphocytes, this does not seem to be the principal mechanism for steroid-induced lymphopenia. Other studies have shown that the lymphopenia is related to redistribution of lymphocytes with increased influx into and decreased efflux from lymphoid organs. 48, 49 Delay in B cell recovery associated with the use of prednisone for GVHD prophylaxis has been reported previously. 50, 51 In our group of patients, the relation between the risk of relapse and lymphocyte recovery persisted even after stratifying for prednisone use; this could be related to the dominant effect of prednisone on B cells, which play a minor role, if any, in the antileukemic action of the graft.
In conclusion, we have shown that slow recovery of lymphocyte counts after allogeneic BMT for AML is a powerful predictor of post-transplantation relapse. This potentially could be combined with other known risk factors for relapse to better identify patients who are at high risk of early relapse after allogeneic BMT for AML. Early identification of these patients will enable us to intervene quickly with immunotherapeutic options described above or to enroll the patients in trials that evaluate novel methods of relapse prevention. These principles also probably apply to allogeneic peripheral blood SCT as well; however, this needs to be verified by further studies. We have also shown that the use of prednisone as part of GVHD prophylaxis can have a significant effect on lymphocyte recovery and this should be taken into consideration when evaluating lymphocyte recovery as a prognostic marker.
